PeerView Clinical Pharmacology CME/CNE/CPE Video - Jubilee Brown, MD - Changing Tides in Advanced Endometrial Cancer: A Visual Exploration of Current and Emerging Strategies to Maximize the Potential of Cancer Immunotherapies

Jubilee Brown, MD - Changing Tides in Advanced Endometrial Cancer: A Visual Exploration of Current and Emerging Strategies to Maximize the Potential of Cancer Immunotherapies

12/15/21 • 33 min

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/YBS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in endometrial cancer examines the evidence for current and emerging treatment strategies and shares evidence-based recommendations for maximizing the potential of immunotherapies to improve outcomes for patients with advanced endometrial cancer. Upon completion of this activity, participants should be better able to: Describe the rationale for integrating biomarker testing and immunotherapy into the management of endometrial cancer, Review current guidelines and clinical trial evidence on new and emerging immune-based treatment strategies in endometrial cancer, Implement the latest guidelines, evidence, and team-based strategies for biomarker testing, immunotherapy selection, and adverse event management in patients with endometrial cancer.

Previous Episode

undefined - Domenica M. Rubino, MD & Donna H. Ryan, MD, FTOS -Gut Feeling: The Increasing Importance of GLP-1–Based Therapies for Personalized Obesity Management

Domenica M. Rubino, MD & Donna H. Ryan, MD, FTOS -Gut Feeling: The Increasing Importance of GLP-1–Based Therapies for Personalized Obesity Management

Go online to PeerView.com/WBN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Obesity is a complex chronic disease that can cause serious health complications. Current guidelines advocate for the use of multiple interventions to address the genetic, behavioral, and metabolic factors that contribute to insufficient weight loss or weight regain. Weight-loss pharmacotherapy is a recommended approach with distinct mechanisms of action that can affect different aspects of obesity pathophysiology. In this activity, based on a recent live web broadcast, leading experts examine the pathophysiology of obesity, focusing on metabolic adaptation and the role of GLP-1 in energy consumption and expenditure and review the latest evidence for GLP-1–based agents. The panel also discusses clinically relevant patient scenarios to offer practical guidance on identifying ideal candidates for weight-loss medications and integrating these medications into individualized treatment plans in order to optimize health outcomes and promote long-term weight loss. Upon completion of this CE activity, participants will be able to: Recognize the role of weight-loss pharmacotherapy used adjunct to other treatment approaches for addressing obesity pathophysiology, including metabolic adaptation, Assess available evidence on current and emerging GLP-1–based weight-loss pharmacotherapies, including long-term efficacy and safety data, Incorporate GLP-1–based weight-loss pharmacotherapy, as appropriate, into individualized, evidence-based treatment plans for long-term obesity management.

Next Episode

undefined - Nirav Shah, MD, MS - Visualizing Progress With BTK Inhibitors: An Animated Journey Through the Mechanisms of Covalent and Noncovalent Options

Nirav Shah, MD, MS - Visualizing Progress With BTK Inhibitors: An Animated Journey Through the Mechanisms of Covalent and Noncovalent Options

Go online to PeerView.com/AMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It’s well known that the BTK inhibitor agent class is highly effective across several B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. Less well understood are the factors that can limit the effectiveness of covalent BTK inhibitors and the emerging strategies that can overcome therapeutic resistance and intolerance, which provide a new option for managing relapsed disease. In this animated, visually enhanced activity, a hematology-oncology expert outlines the clinically relevant mechanistic aspects of covalent and noncovalent BTK inhibitors, mechanisms and patterns of resistance to covalent agents, and rationale for integrating novel approaches to combatting resistance and intolerance. Upon completion of this CE activity, participants will be able to: Summarize the mechanistic and selectivity differences among covalent and noncovalent BTK inhibitors, including their implications for off-target effects, agent safety profiles, and therapeutic intolerance, Describe the mechanisms of BTK inhibitor resistance, including core mechanisms of acquired resistance to covalent agents and how noncovalent inhibitors can overcome resistance mutations.